GTCR/Surmodics: Facing Potential FTC Suit, Companies Allow Brief Review Extension to Early Next Month

Published on Feb 27, 2025

Facing a potential FTC suit against GTCR’s planned $627 million Surmodics (SRDX) buyout, the companies have agreed to extend the antitrust review into early next month and continue discussions with the agency, sources familiar with the matter said.

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2025 The Capitol Forum. All Rights Reserved.